Harlow, United Kingdom

Nicholas Maughan Clayton


 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 24(Granted Patents)


Location History:

  • Stevenage, GB (2005)
  • Harlow, GB (2012)

Company Filing History:


Years Active: 2005-2012

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Nicholas Maughan Clayton

Introduction

Nicholas Maughan Clayton is a notable inventor based in Harlow, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for medical use. With a total of 2 patents, his work has the potential to impact various medical treatments.

Latest Patents

Clayton's latest patents include a compound of formula (I) or a pharmaceutically acceptable derivative thereof. This patent details a process for preparing such compounds, a pharmaceutical composition comprising these compounds, and their use in medicine. Another significant patent involves the use of EP4 receptor ligands in the treatment of neuropathic pain and colon cancer. This invention relates to the use of an EP4 receptor ligand in the manufacture of a medicament for treating neuropathic pain, colon cancer, migraine, and for increasing the latency of HIV infection.

Career Highlights

Throughout his career, Nicholas Maughan Clayton has worked with prominent companies such as SmithKline Beecham Corporation and Glaxo Group Limited. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.

Collaborations

Clayton has collaborated with notable individuals in his field, including Gerard Martin Paul Giblin and Susanne Denise Collins. These collaborations have likely enriched his work and expanded the scope of his inventions.

Conclusion

Nicholas Maughan Clayton's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patents reflect a dedication to improving treatments for various health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…